N/A N=30 Fractional Laser and Ultrasound for Striae Distensae
Stretch Marks
Primary: Live-rater by Two Blinded Dermatologists — 77.27; 22.73 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=45 755nm Alex Laser for Treatment of Stretch Marks
Striae
Primary: Photographic Evaluation of Striae Clearance — 36; 17; 11 areas with striation
Phase 4 N=32 Trial Comparing Treatment of Tretinoin or Superficial Dermabrasion for Stretch Marks
Stretch Marks · Striae · Treatment
Primary: Width of Stretch Marks — 0.199; 0.146; 0.088; 0.077 centimeters
N/A N=17 Clinical Evaluation of the Efficacy of Fractional Radiofrequency for the Treatment and Reduction of Stretch Marks
Stretch Mark
Primary: Percent Change in Volume of Striae Via Antera 3D Imaging System Analysis From Baseline to 16 Weeks Post-final Treatment — -28.3 percentage change from baseline
N/A N=15 Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks
Stretch Marks · Striae Distensae · Cosmetic Appearance of Stretch Marks
Primary: Cosmetic Outcome- Fraction Improving by at Least 1 Point Increase in Overall Appearance of Stretch Marks — 3; 5 Participants
Phase 3 N=52 StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
Phase 2 N=66 Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Stasis Dermatitis
Primary: Percent Change From Baseline in Total Sign Score (TSS) at Week 6: In-person Assessment — -18.07; -32.44 Percent change — p=0.0299
N/A N=36 The Clinical Efficacy And Safety Of SkinStylus Microneedling System
Cicatrix, Hypertrophic
Primary: Number of Participants With Improvement Assessed Using the VAS Scar Scoring System — 22 Participants
Phase 4 N=120 Parastomal Reinforcement With Strattice
Parastomal Hernia
Primary: Occurrence of Parastomal Hernia in Subjects Undergoing Permanent Abdominal Wall Ostomy Creation With and Without Strattice Fascial Inlay. — 6; 7 participants
Phase 2 N=15 StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
N/A N=52 Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM
Obstructed Defecation Syndrome · Rectocele · Intussusception
Primary: Quality of Life — 3.2; 3.7; 2.8; 3.3 units on a scale — p=0.1340
N/A N=22 Human Skin Test Model in Colostomists
Colostomy Stoma
Primary: Peel Force — 2.6; 2.1; 4.4; 3.4 Newton
Phase 3 N=457 Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
Seborrheic Dermatitis
Primary: Achievement of Success on the Investigator Global Assessment (IGA) at Week 8 — 80; 58 percentage of participants — p=<0.0001
N/A N=22 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port-Wine Stain
Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage
N/A N=17 Immediate Postmastectomy Breast Reconstruction (Strattice Breast)
Breast Cancer
Primary: Histology Sample Evaluations Assessing Incorporation of StratticeTM Reconstructive Tissue Matrix — 0; 82.8; 17.2; 0 percentage of breasts
N/A N=60 Prospective Randomized Trial of Stratafix vs. Vicryl in Total Hip Arthroplasty.
Wound; Hip
Primary: Time to Close, Minutes — 18.0; 21.0 minutes